LASERS IN DENTAL TREATMENT WITHOUT NEEDLES AND DRILLS
Dr Omar Zuaiter
Co-Founder & Chief Executive Officer, Dentroid
Alaa Habeb
Co-Founder & Chief Technology Officer, Dentroid
Professor Laurence Walsh
Chief Dental Officer, Dentroid &
Emeritus Professor, School of Dentistry, University of Queensland &
Adjunct Professor, Griffith University, Queensland
Professor Heiko Spallek
Member Scientific Advisory Committee, Dentroid &
Head of School and Dean of The University of Sydney School of Dentistry
BENCH SIDE STORY CASE STUDY
Filmed in Brisbane, Canberra & Sydney | December 2024
In 2017, Dr. Omar Zuaiter and Alaa Habeb launched Dentroid, a dental technology startup with a mission to make dentistry a kinder and friendlier experience for patients and dentists using photonics (using laser technology) and robotics, as alternatives to needles, drills and sprays. The vision for the startup is to have dentistry adopt laser technology, addressing the root causes of dental pain & anxiety, and create a pain-free dental experience.
Dentroid is pioneering the adoption of femtosecond lasers in dentistry which will be their first surgical application outside eye surgery. Unlike conventional dental lasers or rotary instruments, femtosecond lasers have a very unique ability to precisely cut through the most resistant materials without requiring cooling or causing thermal damage. This “cold cutting” creates convenience for the patient, clearer vision for the practitioner and a cleaner environment in the office without microbes laden droplets.
A key distinctive feature of femtosecond laser in “cold cutting” is that it leaves the underlying tissues unharmed with the aim of supporting faster healing with less postoperative complications.
Dentroid envisages femtosecond lasers, combined with their patented miniaturised robotic technology will change the way dental tissues and restorative materials are prepared, processed and bonded not only in clinics but also in dental labs.
To support this mission, Dentroid has assembled a multidisciplinary team of world-renowned experts in dentistry and medicine, engineering, robotics, physics, medical sciences and AI informatics together with commercialisation and growth minds who helped scale startups grow to much larger organisations.
In this Bench Side Story Case Study release, we spoke with some of the key people involved in Dentroid mission and commercialisation journey.
FORWARD LOOKING STATEMENTS
This case study may contain projections and forward-looking statements that involve risks and uncertainties, including statements regarding the potential benefits and success of the drug or therapeutic. Actual results could differ materially from those anticipated in these forward-looking statements due to various factors, including but not limited to the risks and uncertainties associated with drug or device development and regulatory approval processes.
Viewers are advised content is for awareness and entertainment purposes only.
You Might also like
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
-
Landmark research projects tackle critical issues in emergency healthcare
For two decades, the demand for emergency department services in Australia has outpaced population growth and wait times have increased. In 2022-2023 more than 8.8 million emergency department presentations occurred nationwide.
While demand is a contributing factor, EDs are currently being impacted by various factors across the entire health system.
The Emergency Medicine Foundation (EMF) is a non-profit organisation funding innovative Australian research that improves the way people are cared for in a medical emergency. The aim of the research is to deliver better and more effective health services to save lives and money.
-
Improved access to technology needed for people with Type 2 Diabetes needing insulin
The National Diabetes Services Scheme (NDSS) provides subsidised products for diabetes management; however, disparities exist in access to technology between those with Type 1 and Type 2 diabetes. While continuous glucose monitoring (CGM) devices are subsidised for Type 1, they are not available for Type 2 diabetes. ADEA advocates for equitable access to these essential tools, emphasising that all individuals with diabetes deserve the resources necessary for optimal management and reduced risk of complications. Without such technologies, many are forced to rely on finger pricking, which can be inconvenient and unsafe in settings such as the workplace and in higher education.